Oncology · Multiple MyelomaTrial Updateclinicalmid-term

JNJ-87562761 Phase 2 Study Initiated for Relapsed/Refractory Multiple Myeloma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Janssen35 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 6:31:37 AM

Assessment confidence: 66% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 2 study for JNJ-87562761 is significant as it could lead to a new treatment option in the competitive multiple myeloma landscape. Success in this trial may enhance Janssen's portfolio and market positioning in oncology. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 28 ranked evidence items (13 high-relevance).

Strategic Assessment

Success in this trial could enhance Janssen's portfolio in multiple myeloma, potentially leading to a new treatment option that could capture market share. The strongest clinical anchor is A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov), entity match (janssen); patient population match (refractory). In Oncology · Multiple Myeloma, 6 regulatory and 7 competitive items passed relevance filtering for Janssen.

Competitive Pressure

Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG) (FDA). Regulatory pathway relevance (nda). The outcomes of this trial will influence future regulatory submissions and potential approvals for JNJ-87562761, affecting its market entry timeline.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, JNJ-87562761 could capture market share from existing therapies, impacting revenue streams for Janssen and competitors in the multiple myeloma space.
Upside for Janssen may improve if A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma (ClinicalTrials.gov) delivers favorable follow-through.
Bristol Myers Squibb document relevant to the signal.
Upside for Janssen may improve if An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Genentech, Inc.. The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.

What Would Change This Assessment

This becomes more urgent if Monitor the outcomes of the dose escalation and safety assessments, as well as any announcements regarding efficacy results.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.govhigh relevance
Entity match (janssen); Patient population match (refractory)
FDA document
View source
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (refractory)
FDA document
View source
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ClinicalTrials.govhigh relevance
Patient population match (refractory)
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment

RBMS1 enhances PDPK1 mRNA stability to promote multiple myeloma malignancy and M2 macrophage polarization.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
JNJ-87562761

Commercial impact

medium

If successful, JNJ-87562761 could capture market share from existing therapies, impacting revenue streams for Janssen and competitors in the multiple myeloma space.

Regulatory impact

medium

The outcomes of this trial will influence future regulatory submissions and potential approvals for JNJ-87562761, affecting its market entry timeline.

What to watch

Monitor the outcomes of the dose escalation and safety assessments, as well as any announcements regarding efficacy results.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.